描述
Risk of bias or quality assessment for studies included in the spironolactone and female pattern hair loss meta-analysis, evaluating methodological rigor across the evidence base.
More Figures from This Paper
Figure 2
Forest plot or pooled analysis from the spironolactone meta-analysis, presenting combined efficacy data across studies examining oral spironolactone for treating female pattern hair loss.
forest_plot
Figure 4
Pooled analysis indicating that hair loss did not improve or showed only modest improvement in 37.80% (95% CI: 24.88-52.71%) of patients treated with oral spironolactone, with subgroup analyses revealing variable response rates.
forest_plot
Figure 5
Safety outcomes or adverse event analysis from the spironolactone meta-analysis, summarizing the tolerability profile of oral spironolactone when used for female pattern hair loss.
chartFigure 3
ChartSource Paper
The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis.Cite This Figure
 > Source: Majed Aleissa "The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Patter." *Cureus*, 2023. PMID: [37719557](https://pubmed.ncbi.nlm.nih.gov/37719557/)
<figure> <img src="https://pdfs.citedhealth.com/figures/37719557/170.png" alt="Risk of bias or quality assessment for studies included in the spironolactone and female pattern hair loss meta-analysis, evaluating methodological rigor across the evidence base." /> <figcaption>Figure 3. Risk of bias or quality assessment for studies included in the spironolactone and female pattern hair loss meta-analysis, evaluating methodological rigor across the evidence base.<br> Source: Majed Aleissa "The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Patter." <em>Cureus</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37719557/">37719557</a></figcaption> </figure>